Diffuse Large B-Cell Lymphoma, NOS · line 3 · Epcoritamab SC monotherapy for r/r DLBCL ≥3L (EPCORE NHL-1)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | REGIMEN-EPCORITAMAB-MONO-DLBCL-3L |
| ID | IND-DLBCL-3L-EPCORITAMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-01 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ option for r/r DLBCL. Epcoritamab subcutaneous CD20×CD3 bispecific is particularly suited to outpatient-heavy Ukrainian oncology workflow if registered later, though cycle 1 day 15 hospital-monitoring requirement assumes a 24-hour inpatient bed. Bibliographic record SRC-EPCORE-NHL-1-THIEBLEMONT-2023 is available; clinical claim linkage requires dual clinical sign-off. See REGIMEN-EPCORITAMAB-MONO-DLBCL-3L for full dosing schedule and step-up sub-regimen.
Used By
Algorithms
ALGO-DLBCL-3L- ALGO-DLBCL-3L